KOSDAQBiotech & Pharma131030

OPTUS Pharmaceutical

₩5,410▼ 4.08%2026-11-18 close
Market Cap
₩95.5B
Turnover
₩900M
Volume
170K
Shares out.
17.7M
PER
8.6×
PBR
0.5×
EPS
₩692
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

OPTUS Pharmaceutical: Checking Margins Before Capacity Expansion

OPTUS Pharmaceutical holds the top share of Korea's single-use dry eye treatment market and is preparing its second plant, but quarterly operating profit has fallen for two straight quarters since the first quarter of 2026, so margin recovery is the next checkpoint.

  1. 1

    Sales rose from KRW 58.7 billion in 2022 to KRW 87.2 billion in 2025, while the operating margin eased from 11.3% in 2023 to 10.2% in 2025.

  2. 2

    Operating profit in the third quarter of 2026 was KRW 1.24 billion, down 61.6% from a year earlier, while sales fell 2.0% over the same period.

  3. 3

    The second plant has been completed, and annual capacity is planned to rise from 470 million units to 830 million units, with KGMP approval and operation targeted for the first half of 2027.

  4. 4

    The debt ratio rose from 9.5% in 2022 to 15.8% in 2025, with total liabilities of KRW 26.1 billion against total equity of KRW 165 billion at the end of 2025.

  5. 5

    Single-use eye drops account for 99% of sales, so product concentration is high, and SAM Chun Dang Pharm is the largest shareholder.

02

Business structure

OPTUS Pharmaceutical is an ophthalmic specialty company that develops and manufactures eye drops, and its shares have been listed on KOSDAQ since December 2010. The company changed its corporate name in 2022 to strengthen its identity as an eye-care specialist.

As of March 2026, single-use eye drops accounted for 99% of sales, with other products such as eyelid cleansers making up the remaining 1%. Its core product is a single-use eye drop line produced at the Osong plant in Chungcheongbuk-do.

In October 2022 the company raised annual production capacity for single-use eye drops to as much as 470 million units. It has obtained EU GMP, KGMP, CE and ISO 13485 certifications and is pursuing exports to the United States.

In the Korean single-use dry eye treatment market, its share was 10.2% in the first quarter of 2026, placing it first, while the second-ranked company held 8.8%.

In September 2024 it signed an exclusive domestic distribution agreement in Korea for QLOSI, a presbyopia treatment approved by the FDA and licensed from Orasis Pharmaceuticals. The largest shareholder is SAM Chun Dang Pharm, with a 39.36% stake as reported in 2024.

Exports remain small, at KRW 600 million in 2022, or about 1% of sales. Because sales depend heavily on one product family, production capacity and market share are the main drivers of results.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24.1B₩3.2B13.4%
2025Q4₩22.6B₩1.7B7.4%
2026Q1₩23.2B₩2.9B12.5%
2026Q2₩24.6B₩2.3B9.4%
2026Q3₩23.6B₩1.2B5.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩58.7B₩5.3B₩5B9.0%4.0%9.5%
2023₩72.4B₩8.2B₩10.8B11.3%8.0%11.2%
2024₩81.9B₩8.6B₩10.3B10.5%7.2%15.8%
2025₩87.2B₩8.9B₩11.4B10.2%6.9%15.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Based on the annual reports, sales were KRW 58.7 billion in 2022, KRW 72.4 billion in 2023 (up 23.5% year on year), KRW 81.9 billion in 2024 (up 13.1%) and KRW 87.2 billion in 2025 (up 6.4%). Sales have risen for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Operating profit was KRW 5.26 billion in 2022, KRW 8.19 billion in 2023 (up 55.7%), KRW 8.59 billion in 2024 (up 4.9%) and KRW 8.88 billion in 2025 (up 3.3%). Growth in both sales and operating profit slowed sharply after 2023, which is the most visible change in the multi-year series.

The operating margin was 9.0% in 2022, 11.3% in 2023, 10.5% in 2024 and 10.2% in 2025, peaking in 2023. Net profit attributable to controlling shareholders was KRW 5.01 billion in 2022, KRW 10.8 billion in 2023 (up 114.7%), KRW 10.3 billion in 2024 (down 4.2%) and KRW 11.4 billion in 2025 (up 10.2%).

Net profit including non-controlling interests was reported at the same amounts for each year. Operating cash flow was KRW 2.05 billion in 2022, KRW 12.4 billion in 2023, KRW 8.9 billion in 2024 and KRW 16.2 billion in 2025, the largest of the four years.

The debt ratio climbed from 9.5% in 2022 to 11.2% in 2023, 15.8% in 2024 and 15.8% in 2025, with total liabilities of KRW 26.1 billion and total equity of KRW 165 billion at year-end 2025.

On a quarterly basis, the third quarter of 2025 posted sales of KRW 24.1 billion and operating profit of KRW 3.22 billion, followed by a fourth quarter with sales of KRW 22.6 billion (down 6.3% quarter on quarter) and operating profit of KRW 1.66 billion (down 48.5%).

The first quarter of 2026 recovered to sales of KRW 23.2 billion (up 2.8%) and operating profit of KRW 2.9 billion (up 74.9%).

Operating profit then fell to KRW 2.32 billion in the second quarter of 2026 (down 20.1%) and to KRW 1.24 billion in the third quarter (down 46.7%, or down 61.6% from a year earlier), marking two straight quarterly declines.

Net profit attributable to controlling shareholders in the third quarter of 2026 was KRW 1.03 billion, down 67.7% year on year. Profit fell far more than sales, which were down 2.0% year on year, suggesting that cost structure shifts weighed on margins.

In the third quarter of 2024, ordinary R&D expenses rose 52% year on year, showing that R&D spending can also move margins.

05

Industry analysis

Korea's single-use dry eye treatment market was valued at KRW 451.5 billion in 2023. OPTUS holds the top position in this market, and its share was 10.2% in the first quarter of 2026, up 0.2 percentage points from a year earlier. The gap with the second-ranked company, which held 8.8%, has been widening gradually.

On the demand side, the population aged 65 and over has grown for ten consecutive years, a backdrop that supports eye-care treatment demand. The company has said it sees sufficient growth potential in the presbyopia treatment market.

In terms of the cycle, the industry is in a phase where capacity additions are widening supply. After the production expansion in 2022, sales rose 23% in 2023, a precedent that suggests supply gains have translated into revenue before.

The company says its 830 million unit capacity will be the largest among domestic single-use eye drop producers. Overseas, it began exporting glaucoma eye drops to Europe in February 2022 and said its Osong plant cleared German regulatory standards.

The key question is whether the company can keep its share while adding supply, and reports suggest the investment effect on sales would become visible from 2027, the year after completion.

06

Outlook

The company has said it completed construction of the second plant and received use approval from the Chungcheongbuk-do Free Economic Zone Authority. The second plant targets Korea Food and Drug Administration KGMP approval and operation within the first half of 2027.

Once running, it will add 360 million units of annual capacity, bringing the total to 830 million units. The timeline differs from earlier reports, however: a 2024 report pointed to a second half of 2026 capacity expansion, and at the 2024 groundbreaking the target completion date was September 30, 2026.

The company has also said it aims for full operation of the second plant by 2028. The plant is intended to ease supply shortages for its own products and to expand contract manufacturing (CMO) work.

The treasury share disposal in March 2026 was described as funding for second plant operations and R&D, but only 575,600 of the 849,985 shares planned for disposal were sold, leaving 274,385 shares unsold after the buyer failed to perform.

The QLOSI domestic launch was targeted for 2026 when the license was signed in 2024. A 2024 report expects the second plant's investment effect to appear in sales from 2027. The next checkpoints are KGMP approval and operation in the first half of 2027, and the quarterly sales and operating margin trend after start-up.

07

Valuation

PER
8.6×
PBR
0.5×
ROE
7.0%
EPS
₩692
BPS
₩11,659
Dividend per share
₩0

The price-to-book ratio is below 1x at the current price, meaning the market capitalization sits under the controlling shareholders' equity book value at the end of 2025.

Net profit attributable to controlling shareholders over the last four quarters totals KRW 11.6 billion, placing the market capitalization in the single-digit range of earnings.

Dividend yield is effectively negligible, so shareholder returns have taken the form of capital measures such as treasury share disposals rather than dividends. The March 2026 disposal was disclosed as a funding source for second plant operations and R&D.

The 2024 report put the KRW 86.0 billion plant investment at 69% of equity at that time. Total liabilities of KRW 26.1 billion against total equity of KRW 165 billion mean financial leverage remains limited. Because earnings are small, the multiple moves sharply with quarterly results.

The same share price can therefore read differently depending on whether profit recovers and whether the new plant lifts margins.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Top share in the domestic market

OPTUS held the top share of 10.2% in the single-use dry eye treatment market in the first quarter of 2026, up 0.2 percentage points from a year earlier. The gap with the second-ranked company at 8.8% has been widening gradually. With the market valued at KRW 451.5 billion in 2023, share gains can translate into a larger revenue base.

Capacity expansion and the second plant

The second plant has been completed, and capacity is set to rise to 830 million units once operating. The company describes this as the largest capacity among domestic single-use eye drop producers. After the 2022 expansion, sales rose 23.5% in 2023, a precedent that suggests added supply can feed revenue growth.

Presbyopia license and CMO expansion

In September 2024 the company signed an exclusive domestic distribution deal for QLOSI, an FDA-approved presbyopia treatment from Orasis Pharmaceuticals. The agreement includes an upfront payment, milestone payments and a royalty of 15% of net sales. The company plans to widen its CMO business once the second plant operates.

09

Bear factors

Declining operating profit

Operating profit fell from KRW 2.9 billion in the first quarter of 2026 to KRW 2.32 billion in the second quarter and KRW 1.24 billion in the third, two straight quarterly declines. Third-quarter operating profit was down 61.6% year on year while sales fell 2.0%. Because profit fell more than sales, margin recovery is the central issue.

Capex burden and rising debt

The KRW 86.0 billion second plant investment was reported in 2024 as equal to 69% of equity at that time. The debt ratio rose from 9.5% in 2022 to 15.8% in 2025. Total liabilities of KRW 26.1 billion remain modest, but the spending comes before the revenue from the plant.

Product concentration and small exports

Single-use eye drops account for 99% of sales, so results are sensitive to prescribing and pricing for one product family. Exports were KRW 600 million in 2022, about 1% of sales, and one report says overseas sales have stayed below KRW 700 million a year. The US export effort is underway, but its contribution to results is still small.

10

Risk factors

Schedule slippage

The expansion timeline was first given as the second half of 2026 in a 2024 report, and the KGMP approval and operation target later moved to the first half of 2027. A delay could push back the payback period on the investment and the timing of CMO contract growth. Utilization and cost improvements need to be tracked in quarterly results.

Controlling shareholder and treasury shares

SAM Chun Dang Pharm holds less than 50% but is treated as having effective control, so OPTUS is consolidated as a subsidiary. In the March 2026 treasury share disposal, 575,600 of 849,985 planned shares were sold, and the company attributed the shortfall to the buyer's failure to perform. How the remaining 274,385 shares are disposed of is a matter for future disclosures.

Returns from licensing and overseas expansion

The domestic launch target for QLOSI was set at 2026 when the license was signed in 2024. Overseas sales remain below KRW 700 million a year, so the results of the US export push are still small. How licensing and milestone costs weigh on the operating margin is another item to check in the next annual report.

11

What to watch next

  1. December 31, 2026

    This is the close of fiscal 2026. The checkpoints are whether operating profit stays near the KRW 1.24 billion of the third quarter of 2026 and whether quarterly sales hold within the KRW 22.6 billion to KRW 24.6 billion range seen since the fourth quarter of 2025.

  2. First half of 2027

    The key item is KGMP approval from the Korea Food and Drug Administration and the start of operation at the second plant. If the plant starts on schedule, annual capacity would rise to 830 million units and supply headroom would begin to show up in results.

  3. Late March 2027

    The 2026 annual report is due. The full-year operating margin can be compared with 10.2% in 2025, and the reasons for the 2026 quarterly profit decline as well as the status of the remaining treasury shares should appear in the filing.

12

Overall view

OPTUS Pharmaceutical holds the top share of Korea's single-use dry eye treatment market, and sales rose from KRW 58.7 billion in 2022 to KRW 87.2 billion in 2025.

Operating margin, however, peaked at 11.3% in 2023 and eased to 10.2% in 2025, and third-quarter 2026 operating profit of KRW 1.24 billion was down 61.6% year on year.

Once the second plant runs, capacity would rise to 830 million units and supply headroom would grow, but the operating target has been set for the first half of 2027, later than an earlier report. The debt ratio rose to 15.8%, with total liabilities of KRW 26.1 billion against equity of KRW 165 billion.

Strengths include market share, capacity and the presbyopia license, while weaknesses include the margin decline, product concentration, the shareholder structure and unsold treasury shares. At the end of 2025 the market capitalization was below the book value of equity attributable to controlling shareholders.

The next checkpoints are KGMP approval and start-up in the first half of 2027 and the full-year operating margin in the annual report due in late March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jobkorea.co.kr
  2. jasoseol.com
  3. dailypharm.com
  4. hkn24.com
  5. news.nate.com
  6. pharm.edaily.co.kr
  7. pinpointnews.co.kr
  8. m.finance.daum.net
  9. biotimes.co.kr
  10. pharm.edaily.co.kr
  11. markets.hankyung.com
  12. news.nate.com
  13. jobkorea.co.kr
  14. orgo.kr
  15. m.dailypharm.com
  16. manilatimes.net
  17. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis